Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases. Its proprietary technology enables controlled and local delivery of nitric oxide via macromolecules in patients with cystic fibrosis.